Drug Trial Radar · NCT04066231
ANTERO-4: VIPUN Gastric Monitoring System in an Erythromycin Model
Last checked: Nov 19, 2026Latest source record: Aug 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
5
Actual
Start
Sep 7, 2019
Primary completion
Mar 10, 2020
Study completion Mar 10, 2020
Sponsor
- Lead sponsor
- Prof Dr Jan TackAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 26, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
It has been demonstrated that the VIPUN Gastric Monitoring System (GMS) can discriminate healthy physiological and pharmacologically-inhibited gastric motility, using a codeine-model in healthy adults (S60320 / AFMPS80M0687). Erythromycin is a gastroprokinetic agent, known to stimulate gastric contractility. A single dose of 200 mg erythromycin has been shown to induce a prolonged period of enhanced phasic contractile activity. The primary aim of this investigation is to validate the ability of the VIPUN GMS to discriminate between normal and pharmacologically-enhanced fasting gastric motility in healthy adults. The performance of the VIPUN GMS can be enhanced by data-driven optimization of the VIPUN Motility Algorithm, used to quantify gastric motility.
Conditions
- Gastric Motility
Interventions
VIPUN GMSDevice
Motility is measured for 4 hours with the VIPUN Gastric Monitoring System (GMS).
Erythromycin LactobionateDrug
Test model: Erythromycin has gastroprokinetic properties. The primary aim of this investigation is to validate the ability of the VIPUN GMS to discriminate between normal and pharmacologically-enhanced fasting gastric motility in healthy adults. Erythromycin Lactobionate infusion: 200 mg i.v. infusion over a period of 20 minutes. Note: Erythromycin is not labeled as a gastroprokinetic agent in Belgium.
Primary outcomes
What the sponsor says the trial is designed to measure.
- GBMI baselineTime frame: t = 0 - 119 minutes
- GBMI120 - 139Time frame: t = 120 - 139 minutes
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UZ Leuven
Leuven, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.